Improvement in sequelae of chronic liver disease in patients with Alagille syndrome treated with maralixibat
Year: 2026
Type: article
Study design: Case Report
Abstract: Maralixibat (MRX) is an orally administered, small-molecule ileal bile acid transporter (IBAT) inhibitor used in the treatment of cholestatic pruritus in conditions such as Alagille syndrome (ALGS). MRX's beneficial effects on cholestatic pruritus are well described, however its effects on patients' clinical manifestations of hepatic disease are less well known. We report two cases of patients with ALGS treated with MRX who demonstrated stabilization of their esophageal varices and xanthomas, respectively. Our findings demonstrate the potential role of MRX in improving the extrahepatic manifestations of liver disease in patients with ALGS. Further studies are needed to understand the physiologic mechanisms driving these changes.
Source: JPGN Reports
DOI: 10.1002/jpr3.70262
Institution: University of California San Diego
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $1,900
OpenAlex ID: W7225990079
